Literature DB >> 15999551

Potential prognostic value of circulating levels of vascular endothelial growth factor-A in patients with gastric cancer.

Shigang Ding1, Sanren Lin, Xiuyun Dong, Xueling Yang, Hengy Qu, Shumei Huang, Wenjing Liu, Liya Zhou, Donghui Liu.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the potential prognostic value of the circulating levels of vascular endothelial growth factor-A (VEGF-A) in patients with gastric cancer.
MATERIALS AND METHODS: An ELISA was used to quantify the serum and plasma levels of VEGF-A in 135 patients with gastric cancer and 48 controls with benign gastric diseases diagnosed by gastroendoscopy and histology of the biopsied specimens. Serum VEGF-A levels were assayed in controls (n = 10) and patients with gastric cancer (n = 10) prior to surgery. Further samples from 16 patients with gastric cancer, 3 weeks after tumour excision, were collected.
RESULTS: VEGF-A levels were significantly higher in both serum and plasma from patients with gastric cancer than those from the controls (serum: 342.1 pg/ml vs. 80.0 pg/ml, p < 0.01; plasma: 74.1 pg/ml vs. 23.7pg/ml, p < 0.01). In both cancer patients prior to surgery and controls, serum VEGF-A levels appeared to be unchanged over a 7-day period. However, examination of paired samples from 16 cancer patients collected prior to surgery and 3 weeks post-surgery showed that tumor excision resulted in a significant decrease in VEGF-A levels (Paired t-test, t = 5.4, p < 0.0001).
CONCLUSION: Serum and plasma VEGF-A levels were significantly higher in patients with gastric cancer than in the controls. Serum VEGF-A levels correlated with tumour burden, as VEGF-A levels were significantly lowered following tumour excision in patients with gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15999551

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  6 in total

1.  Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma.

Authors:  Mansour-S Al-Moundhri; A Al-Shukaili; M Al-Nabhani; B Al-Bahrani; I-A Burney; A Rizivi; S-S Ganguly
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

2.  Serum VEGF and VEGF-C values before surgery and after postoperative treatment in gastric cancer.

Authors:  Pedro Villarejo-Campos; David Padilla-Valverde; Raúl Martin Martin; Pablo Menéndez-Sánchez; Teófilo Cubo-Cintas; Jose Antonio Bondia-Navarro; Jesús Martín Fernández
Journal:  Clin Transl Oncol       Date:  2012-07-24       Impact factor: 3.405

Review 3.  Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer.

Authors:  Henrik Nienhüser; Thomas Schmidt
Journal:  Int J Mol Sci       Date:  2017-12-23       Impact factor: 5.923

Review 4.  Gastric Cancer and Angiogenesis: Is VEGF a Useful Biomarker to Assess Progression and Remission?

Authors:  Filipa Macedo; Kátia Ladeira; Adhemar Longatto-Filho; Sandra F Martins
Journal:  J Gastric Cancer       Date:  2017-03-13       Impact factor: 3.720

Review 5.  Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma.

Authors:  Massimiliano Salati; Francesco Caputo; Alessandro Bocconi; Sara Cerri; Cinzia Baldessari; Federico Piacentini; Massimo Dominici; Fabio Gelsomino
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

6.  Impact of Selected Serum Factors on Metastatic Potential of Gastric Cancer Cells.

Authors:  Marta Tkacz; Maciej Tarnowski; Agata Poniewierska-Baran; Karol Serwin; Anna Madej-Michniewicz; Anna Deskur; Bogusław Czerny; Teresa Starzyńska
Journal:  Diagnostics (Basel)       Date:  2022-03-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.